Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice.

Posgai AL, Wasserfall CH, Kwon KC, Daniell H, Schatz DA, Atkinson MA.

Sci Rep. 2017 Feb 13;7:42372. doi: 10.1038/srep42372.

2.

Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.

Rosenthal KS, Mikecz K, Steiner HL 3rd, Glant TT, Finnegan A, Carambula RE, Zimmerman DH.

Expert Rev Vaccines. 2015 Jun;14(6):891-908. doi: 10.1586/14760584.2015.1026330. Epub 2015 Mar 18. Review.

3.

Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.

Skyler JS, Pugliese A.

Diabetes Technol Ther. 2013 Jun;15 Suppl 2:S2-13-S2-20. doi: 10.1089/dia.2013.0107.

4.

Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Kwon KC, Verma D, Singh ND, Herzog R, Daniell H.

Adv Drug Deliv Rev. 2013 Jun 15;65(6):782-99. doi: 10.1016/j.addr.2012.10.005. Epub 2012 Oct 23. Review.

5.

AB toxins: a paradigm switch from deadly to desirable.

Odumosu O, Nicholas D, Yano H, Langridge W.

Toxins (Basel). 2010 Jul;2(7):1612-45. doi: 10.3390/toxins2071612. Epub 2010 Jun 25. Review.

6.

Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit.

Odumosu O, Payne K, Baez I, Jutzy J, Wall N, Langridge W.

Immunobiology. 2011 Apr;216(4):447-56. doi: 10.1016/j.imbio.2010.09.008. Epub 2010 Sep 24.

7.

Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection.

Fousteri G, Chan JR, Zheng Y, Whiting C, Dave A, Bresson D, Croft M, von Herrath M.

Diabetes. 2010 Dec;59(12):3148-58. doi: 10.2337/db10-0561. Epub 2010 Sep 23.

8.

Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma.

Fousteri G, Dave A, Bot A, Juntti T, Omid S, von Herrath M.

Diabetologia. 2010 Sep;53(9):1958-70. doi: 10.1007/s00125-010-1777-x. Epub 2010 May 20.

9.

The anti-insulin trimolecular complex in type 1 diabetes.

Michels AW, Nakayama M.

Curr Opin Endocrinol Diabetes Obes. 2010 Aug;17(4):329-34. doi: 10.1097/MED.0b013e32833aba41. Review.

10.

Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.

Eisenbarth GS.

Diabetes. 2010 Apr;59(4):759-74. doi: 10.2337/db09-1855. No abstract available.

11.

Activation of insulin-reactive CD8 T-cells for development of autoimmune diabetes.

Wong FS, Siew LK, Scott G, Thomas IJ, Chapman S, Viret C, Wen L.

Diabetes. 2009 May;58(5):1156-64. doi: 10.2337/db08-0800. Epub 2009 Feb 10.

12.

Insulin as an autoantigen in NOD/human diabetes.

Zhang L, Nakayama M, Eisenbarth GS.

Curr Opin Immunol. 2008 Feb;20(1):111-8. doi: 10.1016/j.coi.2007.11.005. Review.

Supplemental Content

Support Center